Mark C. McKenna, Director at Apogee Therapeutics, Inc. (APGE), bought 20,000 shares at $49.85 ($991K) on 2024-12-12, disclosed to the SEC on 2024-12-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.02 | 7,500 | $368K | 37.1% |
| 2 | $49.85 | 12,500 | $623K | 62.9% |
| Total | $49.54 avg | 20,000 | $991K | 100% |
| Filing → |
| RXDX | SELL | 2023-02-17 | $7.7M | — | Filing → |
| RXDX | SELL | 2023-01-19 | $3.0M | — | Filing → |
| BHC | SELL | 2019-08-21 | $470K | — | Filing → |